Clean Needles, Banned Botanicals, and the Economics of Keeping Addiction Alive
The same national organization telling counties to restrict kratom access is telling them to expand needle exchanges. That is not a contradiction. It is a policy framework — and the financial incentives behind it are identifiable.
TL;DR: The Harm Reduction Paradox
- The contradiction: States like Alabama, Louisiana, and Vermont fund needle exchanges while criminalizing kratom — the botanical with the best documented evidence for helping people exit opioid dependency entirely.
- What each intervention does: Needle exchanges keep people alive while they remain dependent. Kratom, for a documented majority of prior opioid users, helps them stop using opioids — at $30-60 a month, with no prescription.
- The financial architecture: Clinical addiction treatment (methadone, buprenorphine, residential care) generates continuous billable revenue. A person managing recovery with a $40/month botanical generates none.
- Who testifies: Legislative testimony favoring kratom bans is disproportionately drawn from treatment centers and health systems with a direct financial stake in the treatment model kratom competes with.
- The evidence: A Recovery Research Institute survey found ~70% of kratom users with prior opioid use report using it to cut back or quit opioids. Johns Hopkins research (Garcia-Romeu et al., 2020, N=2,798) found fewer than 3% develop kratom use disorder.
- The outcome when people are heard: Rhode Island reversed its kratom ban in April 2026. North Dakota's House rejected a total ban 46-47 in a special session called specifically to pass it.
The Contradiction
Alabama banned kratom in 2016, classifying mitragynine and 7-hydroxymitragynine as Schedule I controlled substances under Alabama Code § 20-2-23. Knowing possession is a Class C felony. The Alabama Attorney General issued a statewide cease-and-desist enforcement wave in March 2026, actively pursuing retailers who sold products containing kratom alkaloids. Alabama is serious about keeping kratom out of the state.
Alabama also operates syringe services programs funded by federal and state grants, providing clean needles to people who inject drugs. The CDC supports these programs. The federal government funds them. Alabama accepts that funding.
The Pattern Across States
Alabama — Kratom banned as Schedule I since 2016 (Ala. Code § 20-2-23); statewide cease-and-desist enforcement wave, March 2026. Operates federally and state-funded syringe services programs.
Louisiana — Kratom banned August 2025 under Senate Bill 154, Schedule I with criminal penalties for possession, sale, and manufacture. Also operates needle exchange programs.
Vermont — Kratom banned as a controlled substance. Simultaneously maintains one of the most comprehensive harm reduction infrastructures in the country, including its nationally recognized Hub and Spoke model for medication-assisted treatment.
None of these states is wrong to fund needle exchanges. Syringe services programs save lives by reducing HIV and hepatitis C transmission among people who inject drugs. The evidence base is strong and uncontroversial. The CDC, SAMHSA, and the National Institutes of Health all support them. Needle exchanges are good harm reduction policy.
This Is Not an Argument Against Needle Exchanges
The question this article examines is not whether needle exchanges are good policy. The question is why states that fund needle exchanges simultaneously ban the botanical with the strongest documented evidence for helping people exit opioid dependency entirely.
What Needle Exchanges Actually Do
Syringe services programs are a harm reduction intervention. They reduce the transmission of blood-borne infectious diseases among people who inject drugs. They provide naloxone, disease testing, and referral to treatment services. They create touchpoints between the healthcare system and a population that is otherwise difficult to reach.
What they do not do, and are not designed to do, is get people off drugs. That is not a criticism. It is a description of purpose. Harm reduction, by its own definition, seeks to reduce the negative consequences of drug use without necessarily prioritizing cessation. A clean needle keeps someone alive who might otherwise contract HIV or hepatitis C. It does not address the dependency that brought them to the needle exchange.
This is valuable. Staying alive is the prerequisite for recovery. But it is a different intervention from one that addresses the underlying dependency.
What Kratom Actually Does
A Recovery Research Institute study found that approximately 70 percent of kratom users with prior opioid use reported using kratom specifically to cut back or quit opioids. This is not a survey of a clinical population enrolled in treatment. This is a survey of people who made an independent decision to use a botanical supplement and what they used it for.
What the Research Shows
~70% of kratom users with prior opioid use report using kratom specifically to cut back or quit opioids (Recovery Research Institute).
Under 3% of kratom users develop moderate or severe kratom use disorder by DSM-5 criteria (Garcia-Romeu et al., 2020, Drug and Alcohol Dependence, PMID 32029298, N=2,798, Johns Hopkins University).
For comparison: buprenorphine, the active ingredient in Suboxone and the pharmaceutical first-line response to opioid use disorder, produces its own physical dependence with a prolonged discontinuation process that many patients describe as more difficult than the opioid they were originally managing.
"If we take kratom out of the market immediately without education, people are going to turn to fentanyl, and fentanyl is what kills everyone."
— Essentia Health medical toxicologist
Kratom does not keep people alive while remaining dependent. For a documented majority of users with prior opioid use, it helps them get off opioids entirely. At thirty to sixty dollars a month. Without a prescription. Without a clinic visit. Without insurance. Without a treatment center intake assessment.
That last part matters.
The Financial Architecture of Ongoing Addiction
When someone manages opioid use disorder with kratom at forty dollars a month, no revenue is generated by the healthcare system. No clinic visit billed to Medicaid. No Suboxone prescription filled at a pharmacy. No treatment center intake. No monthly monitoring appointment. No urine screen. No counseling session. No case management fee.
When someone manages opioid use disorder through the clinical system, the revenue profile looks different. Methadone maintenance requires daily clinic visits in most states, generating ongoing facility fees and clinical billing. Buprenorphine requires physician prescribing, pharmacy fulfillment, and regular monitoring appointments. Residential treatment generates per-diem facility revenue. Intensive outpatient generates per-session billing. Case management generates per-contact fees. The healthcare response to opioid use disorder is a revenue-generating system, and it generates revenue continuously as long as people remain in the system.
This is not inherently corrupt. These services provide real value. People get better through clinical treatment. The problem arises when the financial architecture of the system creates institutional incentives that favor ongoing treatment engagement over exit from treatment, and when the policy environment is shaped by institutions with those incentives — the same dynamic documented in detail in Follow the Money: the complete financial analysis of lobbying spending, political contributions, and the addiction treatment market kratom threatens.
Industries Built on Ongoing Dependency
Indivior, which manufactures Suboxone Film, has vigorously defended its patents and market position, including a high-profile legal battle against generic competitors.
The methadone clinic industry is a significant sector. Addiction treatment center revenues have grown substantially during the opioid crisis. These are industries that exist because of ongoing opioid dependency, and they have policy interests that align with the continuation of the conditions that generate their revenue.
The Competitor, Not the Complement
A botanical that helps people exit the addiction treatment system at forty dollars a month is not a complement to these revenue streams. It is a competitor.
Who Testifies
When state legislatures hold hearings on kratom legislation, the testimony in favor of bans and restrictions follows a consistent pattern. Treatment center staff describe patients presenting with kratom use. Addiction medicine physicians describe clinical encounters with kratom-dependent patients. Harm reduction organization staff describe seeing kratom use in their programs. Representatives from hospital systems characterize kratom as a public health threat.
These are not neutral parties. They are institutions with financial stakes in the classification of kratom as a substance requiring treatment. A patient who walks into a treatment center presenting with kratom use generates billable clinical activity. A patient who self-managed opioid recovery with kratom at forty dollars a month and never sought clinical treatment generates nothing.
Kratom withdrawal "is worse than just a fentanyl or heroin withdrawal."
— Registered nurse, Providence House addiction recovery center, Arnegard ND, testifying in North Dakota's 2026 special session in favor of a total kratom ban
Providence House is an addiction treatment facility. Its operational sustainability depends on patients who need treatment.
7-OH and its derivatives function "more like an opioid," binding to opioid receptors in ways that cause problems.
— Dr. Brock Ashmore, Sanford Health, quoted in InForum in the weeks before North Dakota's special session
Sanford Health is the regional healthcare system that has expanded to control significant portions of the healthcare market across South Dakota, North Dakota, and Minnesota. Its institutional interests include the addiction treatment revenue streams that kratom competes with directly.
The Pattern Is Consistent Across States
The voices testifying for kratom bans are disproportionately drawn from institutions that financially benefit from the treatment model that kratom competes with.
The Policy Decision Being Made
A state that funds syringe services programs while banning kratom is not choosing between harm reduction and prohibition. It is choosing between two different harm reduction approaches with very different outcomes for the institutions that profit from addiction treatment.
Needle exchanges keep people alive and in the addiction treatment system's potential orbit. They are good for public health metrics, good for disease prevention, and they do not threaten the revenue model of clinical addiction treatment. They are supported by the same healthcare institutions that testify against kratom.
Kratom helps people exit the addiction treatment system at forty dollars a month. It threatens the revenue model of clinical addiction treatment. It is opposed by the same healthcare institutions that support needle exchanges.
Not a Coincidence
This is not a coincidence. It is a predictable outcome of a policy environment shaped by institutions with financial interests in a specific treatment model.
When People Are Actually Heard
Rhode Island tried prohibition, lived with it, and reversed its kratom ban in April 2026, becoming the first state to do so after reviewing the evidence.
The North Dakota House rejected a total kratom ban 46-47 in a special session called specifically to pass it, and which cost the state over $200,000 to convene. The deciding vote came from a representative who noted that people who use kratom responsibly were present at the hearing but were never given an opportunity to testify.
The people who use kratom responsibly, who get off opioids with it, who function normally on it, who would be in fentanyl's orbit without it, do not have institutions speaking for them. They are individuals navigating a system designed and funded by institutions that benefit from their continued dependency.
The Question the Evidence Raises
Public health policy that funds needle exchanges is making a statement: we would rather keep people alive in addiction than let them die.
Public health policy that funds needle exchanges and simultaneously bans the botanical most documented to help people exit addiction is making a different statement. It is maintaining the harm reduction infrastructure that keeps the addiction treatment system's patient population alive and engaged, while removing the option that helps people leave that population entirely.
The financial beneficiaries of that policy choice are identifiable. The people harmed by it are also identifiable: working adults managing chronic pain and opioid recovery without robust healthcare access, who found something that worked at a price they could afford, and are being told by their state that their health management is a felony.
The Harm Reduction Paradox
That is the harm reduction paradox. It is not complicated. It is just rarely stated directly.
The Kratom Truth Project documents the financial conflicts and policy contradictions behind botanical prohibition campaigns. The full investigation into the pharmaceutical patent trail is at The Patent Race: Synthetic Kratom & the Cannabis Playbook. The primary source investigation into the statistics behind the bans is at How a Crisis Gets Built.
Continue the Investigation
The Patent Race
Pharmaceutical companies are patenting synthetic kratom while lobbying to ban the natural plant. The cannabis playbook exposed: ban natural, patent synthetic, charge 20x more.
Follow the Money
The complete financial analysis: lobbying spending, political contributions, revolving door between FDA and pharma, and the $258 billion addiction treatment market.
How a Crisis Gets Built
The statistics behind America's kratom bans don't hold up against the primary sources: the deaths that aren't what they're called, the escalation that was measured into existence, and the patent trail behind the scheduling push.
Sources & Documentation
Every claim in this investigation is drawn from public statute text, published research, on-record quotes, and legislative proceedings. Verify it yourself.
State Policy & Legal Documentation
- Alabama Code § 20-2-23 — Schedule I classification of mitragynine and 7-hydroxymitragynine (2016); Alabama Attorney General statewide cease-and-desist enforcement wave, March 2026
- Louisiana Senate Bill 154 — Schedule I classification of kratom, August 2025
- Vermont's Hub and Spoke model for medication-assisted treatment
- North Dakota House vote rejecting a total kratom ban, 46-47, 2026 special session
- Rhode Island kratom ban reversal, effective April 2026
Clinical & Research Evidence
- Recovery Research Institute study — approximately 70% of kratom users with prior opioid use report using kratom to cut back or quit opioids
- Garcia-Romeu et al., 2020, Drug and Alcohol Dependence, PMID 32029298, N=2,798, Johns Hopkins University — fewer than 3% of kratom users develop moderate or severe kratom use disorder by DSM-5 criteria
- CDC, SAMHSA, and National Institutes of Health syringe services program guidance and evidence base
Institutional & Testimony Sources
- Public statement, Essentia Health medical toxicologist, on the risk of removing kratom access without education
- Testimony of a registered nurse, Providence House addiction recovery center (Arnegard, ND), North Dakota 2026 special session
- Dr. Brock Ashmore, Sanford Health, quoted in InForum ahead of North Dakota's special session
- National Association of Counties — September 2026 guidance encouraging county-level kratom restriction, alongside its strategy brief recommending expansion of syringe services programs
- Indivior (Suboxone Film) patent litigation against generic competitors
Cross-References
- The Patent Race: Synthetic Kratom & the Cannabis Playbook — the pharmaceutical patent trail
- Follow the Money — the financial forces behind kratom prohibition
- How a Crisis Gets Built — the statistics behind the bans
Methodology Note
- State ban and enforcement details drawn from statute text and public Attorney General/legislative records
- Dependence and cessation figures cited to their original published studies, not secondary summaries
- Testimony quotes drawn from on-record legislative hearings and named media outlets
- Institutional financial interests described only where a documented revenue relationship exists (patent litigation, treatment billing structures, healthcare system market share)
SHARE THIS INVESTIGATION
States fund needle exchanges and ban kratom. The financial incentives explain why — and the people who use kratom responsibly are the ones paying for it.
Copy link to this investigation:
✓ Link copied to clipboard!
The Harm Reduction Paradox
Public health policy that funds needle exchanges is making a statement: we would rather keep people alive in addiction than let them die.
Public health policy that funds needle exchanges and simultaneously bans the botanical most documented to help people exit addiction is making a different statement — maintaining the infrastructure that keeps the treatment system's patient population alive and engaged, while removing the option that helps people leave that population entirely.
The financial beneficiaries of that policy choice are identifiable. So are the people harmed by it.